We are excited to announce improvements to BiomarkerBase, increasing the coverage and analysis of literature. We’ve added biomarkers sourced only from literature, representing biomarkers in an earlier stage of development.  With this addition there are two main benefits:

  1. Access to biomarker and supporting information that is in an early stage of development (3x more biomarker coverage)
  2. Categorization of publications by supporting, contradicting, inconclusive and co-mentioned for a biomarker and disease

We are especially excited about the second benefit.  Categorizing literature as supportive or contradictory directly aligns with how researchers evaluate biomarkers for their programs.

Check out this video overview for more information.

 

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access